Adarsh Aratikatla, Samir Ghandour, Nicola Maffulli, Manu Gupta, Ashim Gupta
{"title":"同种异体脐带组织治疗颞下颌关节损伤。","authors":"Adarsh Aratikatla, Samir Ghandour, Nicola Maffulli, Manu Gupta, Ashim Gupta","doi":"10.3389/fpain.2023.1281277","DOIUrl":null,"url":null,"abstract":"<p><p>The temporomandibular joint (TMJ) is crucial for functions of daily living such as mastication and articulation. Common TMJ issues include osteoarthritis, internal derangement, and myofascial pain dysfunction. Conservative methods such as physical therapy and medications are used, with surgical options such as arthroscopy and replacement for severe cases. Emerging regenerative medicine explores non-surgical treatments using human stem cells from umbilical cord derivatives, showing potential for tissue regeneration in TMJ disorders. A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases, adhering to PRISMA guidelines, aiming to identify relevant articles published in English until August 2023. The search used specific terms to target <i>in vitro</i>, preclinical, and clinical studies on umbilical cord (UC)-derived tissue and mesenchymal stem cells (MSCs) for treating TMJ disorders. The search was extended to three clinical trial registries for on-going investigations related to UC tissue and MSCs for TMJ disorder management. The studies included in this article report the safety and efficacy profiles of allogenically acquired, umbilical cord-derived tissues and associated mesenchymal stem cells for temporomandibular joint ailments, future adequately powered, randomized controlled trials are warranted to conclusively justify the clinical use of this biologic therapy.</p>","PeriodicalId":73097,"journal":{"name":"Frontiers in pain research (Lausanne, Switzerland)","volume":"4 ","pages":"1281277"},"PeriodicalIF":2.5000,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627879/pdf/","citationCount":"0","resultStr":"{\"title\":\"Allogenic umbilical cord tissue for temporomandibular joint injuries.\",\"authors\":\"Adarsh Aratikatla, Samir Ghandour, Nicola Maffulli, Manu Gupta, Ashim Gupta\",\"doi\":\"10.3389/fpain.2023.1281277\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The temporomandibular joint (TMJ) is crucial for functions of daily living such as mastication and articulation. Common TMJ issues include osteoarthritis, internal derangement, and myofascial pain dysfunction. Conservative methods such as physical therapy and medications are used, with surgical options such as arthroscopy and replacement for severe cases. Emerging regenerative medicine explores non-surgical treatments using human stem cells from umbilical cord derivatives, showing potential for tissue regeneration in TMJ disorders. A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases, adhering to PRISMA guidelines, aiming to identify relevant articles published in English until August 2023. The search used specific terms to target <i>in vitro</i>, preclinical, and clinical studies on umbilical cord (UC)-derived tissue and mesenchymal stem cells (MSCs) for treating TMJ disorders. The search was extended to three clinical trial registries for on-going investigations related to UC tissue and MSCs for TMJ disorder management. The studies included in this article report the safety and efficacy profiles of allogenically acquired, umbilical cord-derived tissues and associated mesenchymal stem cells for temporomandibular joint ailments, future adequately powered, randomized controlled trials are warranted to conclusively justify the clinical use of this biologic therapy.</p>\",\"PeriodicalId\":73097,\"journal\":{\"name\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"volume\":\"4 \",\"pages\":\"1281277\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627879/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fpain.2023.1281277\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in pain research (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fpain.2023.1281277","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
颞下颌关节(TMJ)对日常生活功能(如咀嚼和关节)至关重要。常见的TMJ问题包括骨关节炎、内部紊乱和肌筋膜疼痛功能障碍。使用物理治疗和药物治疗等保守方法,并可选择关节镜检查和严重病例的替代手术。新兴的再生医学探索了使用脐带衍生物的人类干细胞进行非手术治疗,显示出TMJ疾病组织再生的潜力。根据PRISMA指南,在PubMed、Embase、Scopus和Web of Science数据库中进行了系统搜索,旨在识别2023年8月之前以英语发表的相关文章。这项研究使用了特定的术语来靶向脐带(UC)衍生组织和间充质干细胞(MSC)治疗TMJ疾病的体外、临床前和临床研究。搜索范围扩大到三个临床试验注册中心,以进行与UC组织和MSCs有关的TMJ疾病管理的持续研究。本文中的研究报告了同种异体获得的脐带来源组织和相关间充质干细胞治疗颞下颌关节疾病的安全性和有效性,未来有必要进行充分的随机对照试验,以最终证明这种生物疗法的临床应用是合理的。
Allogenic umbilical cord tissue for temporomandibular joint injuries.
The temporomandibular joint (TMJ) is crucial for functions of daily living such as mastication and articulation. Common TMJ issues include osteoarthritis, internal derangement, and myofascial pain dysfunction. Conservative methods such as physical therapy and medications are used, with surgical options such as arthroscopy and replacement for severe cases. Emerging regenerative medicine explores non-surgical treatments using human stem cells from umbilical cord derivatives, showing potential for tissue regeneration in TMJ disorders. A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases, adhering to PRISMA guidelines, aiming to identify relevant articles published in English until August 2023. The search used specific terms to target in vitro, preclinical, and clinical studies on umbilical cord (UC)-derived tissue and mesenchymal stem cells (MSCs) for treating TMJ disorders. The search was extended to three clinical trial registries for on-going investigations related to UC tissue and MSCs for TMJ disorder management. The studies included in this article report the safety and efficacy profiles of allogenically acquired, umbilical cord-derived tissues and associated mesenchymal stem cells for temporomandibular joint ailments, future adequately powered, randomized controlled trials are warranted to conclusively justify the clinical use of this biologic therapy.